These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 687104)
41. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution. Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795 [TBL] [Abstract][Full Text] [Related]
42. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. Lynch HT; Snyder CL; Lynch JF; Riley BD; Rubinstein WS J Clin Oncol; 2003 Feb; 21(4):740-53. PubMed ID: 12586815 [TBL] [Abstract][Full Text] [Related]
43. [Familiarity and heredity of tumors in function of an early surgical therapeutic approach]. Ricevuto E; Di Rocco ZC; Cianci G; Bisegna R; Casilli F; De Galitiis F; Cannita K; Calista F; Porzio G; Bafile A; Vicentini R; Resta V; De Rubeis G; Martinotti S; Ficorella C; Marchetti P Suppl Tumori; 2002; 1(3):S89-91. PubMed ID: 12415797 [No Abstract] [Full Text] [Related]
44. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families. Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680 [TBL] [Abstract][Full Text] [Related]
45. Weighing the risks. Genetic counseling for hereditary breast and ovarian cancer. Cummings S AWHONN Lifelines; 2001; 5(3):42-7. PubMed ID: 11982262 [No Abstract] [Full Text] [Related]
46. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Balmaña J; Sanz J; Bonfill X; Casado A; Rué M; Gich I; Díez O; Sabaté JM; Baiget M; Alonso MC Int J Cancer; 2004 Nov; 112(4):647-52. PubMed ID: 15382046 [TBL] [Abstract][Full Text] [Related]
51. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Wagner TM; Möslinger R; Langbauer G; Ahner R; Fleischmann E; Auterith A; Friedmann A; Helbich T; Zielinski C; Pittermann E; Seifert M; Oefner P Br J Cancer; 2000 Apr; 82(7):1249-53. PubMed ID: 10755396 [TBL] [Abstract][Full Text] [Related]
52. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma]. Schmutzler RK; Kempe A; Kiechle M; Beckmann MW Dtsch Med Wochenschr; 1999 May; 124(18):563-6. PubMed ID: 10356583 [No Abstract] [Full Text] [Related]
53. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Agnantis NJ; Paraskevaidis E; Roukos D Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500 [No Abstract] [Full Text] [Related]
54. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868 [TBL] [Abstract][Full Text] [Related]
55. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW Breast J; 2004; 10(6):475-80. PubMed ID: 15569201 [TBL] [Abstract][Full Text] [Related]
56. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing. Kwong A; Chu AT Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201 [TBL] [Abstract][Full Text] [Related]
57. Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter. Kne A; Zierhut H; Baldinger S; Swenson KK; Mink P; Veach PM; Tsai ML J Genet Couns; 2017 Aug; 26(4):697-715. PubMed ID: 27826805 [TBL] [Abstract][Full Text] [Related]
58. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Yamauchi H; Okawa M; Yokoyama S; Nakagawa C; Yoshida R; Suzuki K; Nakamura S; Arai M Breast Cancer Res Treat; 2018 Dec; 172(3):679-687. PubMed ID: 30203341 [TBL] [Abstract][Full Text] [Related]
59. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Fatouros M; Baltoyiannis G; Roukos DH Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826 [TBL] [Abstract][Full Text] [Related]
60. Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. Emery J; Walton R; Murphy M; Austoker J; Yudkin P; Chapman C; Coulson A; Glasspool D; Fox J BMJ; 2000 Jul; 321(7252):28-32. PubMed ID: 10875832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]